Neoadjuvant Chemotherapy with Docetaxel, Carboplatin and Weekly Trastuzumab Is Active in HER2-Positive Early Breast Cancer: Results after a Median Follow-Up of over 4 Years

Ítems similars

• Targeted Intraoperative Radiotherapy Tumour Bed Boost during Breast-Conserving Surgery after Neoadjuvant Chemotherapy – a Subgroup Analysis of Hormone Receptor-Positive HER2-Negative Breast Cancer
  per: Kolberg, Hans-Christian, et al.
  Publicat: (2017)
• Re-Excision Rates in Breast-Conserving Surgery for Invasive Breast Cancer after Neoadjuvant Chemotherapy with and without the Use of a Radiopaque Tissue Transfer and X-ray System
  per: Jamaris, Suniza, et al.
  Publicat: (2019)
• Neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin administered every 3 weeks for Japanese women with HER2-positive primary breast cancer: efficacy and safety
  per: Sugitani, Ikuko, et al.
  Publicat: (2017)
• Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP)
  per: Howell, Sacha J., et al.
  Publicat: (2020)
• Efficacy analysis of trastuzumab, carboplatin and docetaxel in HER-2-positive breast cancer patients
  per: Wu, Di, et al.
  Publicat: (2020)